Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of oral ridaforolimus plus trastuzumab in HER2-positive trastuzumab-refractory metastatic breast cancer
2008-001971-30Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ridaforolimus in breast cancer, sponsored by Merck & Co. Primary endpoint: Objective response rate by modified RECIST. Started Sep 2008; status: completed.
02
Drugs
ridaforolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-001971-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001971-30.